Showing results (1651-1660 of 1,994) with videos related to
Sort By:
Pageof 200
Implementation Science : IS|August 19, 2024
Protocol for a type 3 hybrid implementation cluster randomized clinical trial to evaluate the effect of patient and clinician nudges to advance the use of genomic medicine across a diverse health systemAnna C Raper, Benita L Weathers, Theodore G Drivas, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 5, 2019
Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African AncestryBrittany D Jenkins, Rachel N Martini, Rupali Hire, et al.Archives of Surgery (Chicago, Ill. : 1960)|June 23, 2010
Five-year follow-up of a multicenter, double-blind randomized clinical trial of laparoscopic Nissen vs anterior 90 degrees partial fundoplicationRajwinder S Nijjar, David I Watson, Glyn G Jamieson, et al.Genes & Cancer|September 28, 2010
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival PatternsA Rose Brannon, Anupama Reddy, Michael Seiler, et al.Annals of Surgical Oncology|December 5, 2002
Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV diseaseGarrett M Nash, Leonard B Saltz, Nancy E Kemeny, et al.Molecular Genetics & Genomic Medicine|August 4, 2019
Research participants' experiences with return of genetic research results and preferences for web-based alternativesJill B Gaieski, Linda Patrick-Miller, Brian L Egleston, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2017
Multiple Endocrine Neoplasia and Hyperparathyroid-Jaw Tumor Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in ChildhoodJonathan D Wasserman, Gail E Tomlinson, Harriet Druker, et al.Nature|June 14, 2017
Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistanceSydney M Shaffer, Margaret C Dunagin, Stefan R Torborg, et al.JCI Insight|November 2, 2019
O-GlcNAc transferase suppresses necroptosis and liver fibrosisBichen Zhang, Min-Dian Li, Ruonan Yin, et al.Cancer Discovery|December 28, 2012
Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancerSusan M Domchek, Jiangbo Tang, Jill Stopfer, et al.Pageof 200